As the landscape of mental health evolves, we believe the biggest opportunities for innovation lies at the nexus of drug development and therapy delivery.

Enter Emyria's distinctive dual model: Clinical services paired with cutting-edge drug development.

With our recent acquisition of the Pax Centre (completed today) we are taking the first bold step in broadening our clinical service reach in mental health care. This strategic move boosts our capacity to improve patient lives today and is an investment into our tomorrow. By generating sustainable revenues and capturing critical data from our larger clinical footprint, we're supporting our proprietary drug development programs in MDMA analogies and CBD dose forms. By this approach we can create an immediate impact on mental health care and position ourselves to have a global influence in the days ahead.